Epilepsy

Praxis Precision Medicines to Present Data from Rare Disease Programs at the American Epilepsy Society 2021 Annual Meeting

Private Securities Litigation Reform Act, Judgement, Security (finance), Review, Brain, Epilepsy, Annual report, AES, Central nervous system, U.S. Securities and Exchange Commission, COVID-19, Goal, SYNGAP1, Twitter, Research, Florey Institute of Neuroscience and Mental Health, GLOBE, Mental health, Central nervous system disease, Depression, Neurological disorder, LinkedIn, Movement disorders, ASO, American Epilepsy Society, CNS, NASDAQ, Pharmaceutical industry, Communications satellite

BOSTON, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that data from its rare disease programs will be delivered in three presentations at the American Epilepsy Society 2021 Annual Meeting, held December 3-7, 2021 in Chicago.

Key Points: 
  • BOSTON, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that data from its rare disease programs will be delivered in three presentations at the American Epilepsy Society 2021 Annual Meeting, held December 3-7, 2021 in Chicago.
  • We look forward to presenting data at AES on our small molecule rare disease programs, including PRAX-562, a persistent sodium channel blocker, and our KCNT1 inhibitor, said Steven Petrou, Ph.D., chief scientific officer and co-founder of Praxis.
  • As these programs have advanced, our portfolio of differentiated treatment approaches for rare epilepsies with significant unmet need has expanded and progressed.
  • Praxis undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

Anavex Life Sciences to Present at the 4th Annual Evercore ISI HealthCONx Conference

Retrieved on: 
Monday, November 29, 2021
Patient, Research, Degenerative disease, Amyloid, Conference, Annual report, Rett syndrome, Dementia, Cancer, The Michael J. Fox Foundation, Government budget balance, SEC, Doctor of Philosophy, Central nervous system, Therapy, Nature, Lists of diseases, Pain, Mouse, Twitter, GLOBE, Adult, Central nervous system disease, Instagram, LinkedIn, Epilepsy, CNS, Pharmaceutical industry

About Anavex Life Sciences Corp.

Key Points: 
  • About Anavex Life Sciences Corp.
    Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimers disease, Parkinsons disease, Rett syndrome and other central nervous system (CNS) diseases, pain, and various types of cancer.
  • ANAVEX2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors.
  • Fox Foundation for Parkinsons Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX2-73 for the treatment of Parkinsons disease.
  • All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Supernus Pharmaceuticals Targeted in Ransomware Incident

Retrieved on: 
Wednesday, November 24, 2021
Central nervous system disease, ADHD, GLOBE, Central nervous system, Torticollis, Depression, Epilepsy, Migraine, CNS, NASDAQ, Company, Fine chemical, Cryptocurrency, Pharmaceutical industry

ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company, today announced that it was the recent target of a ransomware attack. The attack had no significant impact on the business and did not cause any serious disruption to the Company’s operations. The Company continues to operate without interruption and does not currently anticipate paying any ransom amounts to any criminal ransomware group.

Key Points: 
  • ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company, today announced that it was the recent target of a ransomware attack.
  • The Company continues to operate without interruption and does not currently anticipate paying any ransom amounts to any criminal ransomware group.
  • Upon detection of the ransomware, the Company notified government authorities, engaged cybersecurity experts and its outside law firm, and commenced its recovery process.
  • Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals

Retrieved on: 
Wednesday, November 24, 2021
Transfer, Section 13, Nasdaq, Milestone, Company, Central nervous system, ADHD, Risk, GLOBE, Central nervous system disease, Depression, Â, CNS, Securities Exchange Act of 1934, Private Securities Litigation Reform Act, Security (finance), CEO, LLP, Time, Achievement, CVR Partners, DGCL, Torticollis, U.S. Securities and Exchange Commission, Amantadine, CVR, Cooley LLP, Contingent value rights, Dyskinesia, Secretary of State of Delaware, Prescription, LLC, Adult, Tablet, FDA, Government, Delaware General Corporation Law, Growth, Patient, Safety, Acquisition, Jefferies Group, Capsule, ADMS, Tax, Topiramate, Epilepsy, Migraine, NASDAQ, Fine chemical, Pharmaceutical industry

ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS).

Key Points: 
  • ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS).
  • Adamas fits squarely within our corporate development strategy, adding a late-stage commercial product with significant revenue, said Jack Khattar, President and CEO of Supernus Pharmaceuticals.
  • Following the completion of the Offer, Supernus completed the acquisition of Adamas through the merger of Reef with and into Adamas, without a vote of Adamas stockholders in accordance with Section251(h) of the General Corporation Law of the State of Delaware (DGCL), with Adamas surviving the merger as a wholly-owned subsidiary of Supernus.
  • Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Praxis Precision Medicines to Present at Piper Sandler’s 33rd Annual Virtual Healthcare Conference

Conference, Brain, Praxis, Central nervous system, Investor, Media, Twitter, GLOBE, Central nervous system disease, Depression, Piper, Neurological disorder, Webcast, Movement disorders, LinkedIn, Epilepsy, CNS, NASDAQ, Event, Pharmaceutical industry

BOSTON, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that management will participate in a fireside chat at Piper Sandlers 33rd Annual Virtual Healthcare Conference on Thursday, December 2, 2021 at 10:30 a.m.

Key Points: 
  • BOSTON, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that management will participate in a fireside chat at Piper Sandlers 33rd Annual Virtual Healthcare Conference on Thursday, December 2, 2021 at 10:30 a.m.
  • A replay of the webcast will be available on Praxis website for 90 days following the event.
  • Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance.
  • Praxis is applying insights from genetic epilepsies to broader neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain.

Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Year End Financial Results

Retrieved on: 
Wednesday, November 24, 2021
Patient, Research, Scientific Reports, Degenerative disease, DSMB, Amyloid, Trial of the century, Review, Safety, Conference, Annual report, ALS, Rett syndrome, Fragile X syndrome, Dementia, Cancer, The Michael J. Fox Foundation, Precision medicine, AVATAR, Clinical trial, Government budget balance, Human, SEC, Doctor of Philosophy, Central nervous system, Attention deficit hyperactivity disorder predominantly inattentive, Therapy, Telephone, Lists of diseases, Pain, Nature, Mouse, Twitter, GLOBE, Adult, Conference call, Positron emission tomography, Central nervous system disease, PET, EDGAR, Instagram, Amyotrophic lateral sclerosis, Webcast, LinkedIn, Autism, SIGMAR1, Epilepsy, CNS, Disease, OLE, Pharmaceutical industry, Animal, Spice

Top-line results from the second placebo-controlled AVATAR Phase 2/3 ANAVEX2-73-RS-002 study for the treatment of adult patients with Rett syndrome are expected around year end 2021.

Key Points: 
  • Top-line results from the second placebo-controlled AVATAR Phase 2/3 ANAVEX2-73-RS-002 study for the treatment of adult patients with Rett syndrome are expected around year end 2021.
  • Top-line results from the placebo-controlled Phase 1 ANAVEX3-71-001 study evaluating ANAVEX3-71 in humans are expected around year end 2021.
  • Top-line results from the placebo-controlled Phase 2b/3 ANAVEX2-73-AD-004 study for the treatment of Alzheimers disease are expected 2H 2022.
  • On August 26, 2021, Anavex announced that preclinical data of ANAVEX2-73 in Fragile X Syndrome was published in the peer-reviewed journal, Scientific Reports.

Global Neuroprotection Markets, Methods, Drugs, and Competitive Landscape Report 2021-2025 & 2030 with Focus on Stroke CNS Injury, Alzheimer Disease, Parkinson Disease, Multiple Sclerosis, Epilepsy - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 23, 2021
Health, Pharmaceutical, Anesthetic, Method, Table, Anesthesia, Time, Multiple sclerosis, Neurodegeneration, Anti-inflammatory, Neuroprotection, Alzheimer's disease, Antioxidant, Retinal degeneration, Nervous system, Degenerative disease, Conditional sentence, Literature, Amyotrophic lateral sclerosis, Parkinson's disease, Traumatic brain injury, Company, Propofol, Epilepsy, CNS, Huntington's disease, Apoptosis, Stroke, Frankincense, Pharmaceutical industry

The "Neuroprotection - Methods, Drugs, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Neuroprotection - Methods, Drugs, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • Some of the agents are old established pharmaceuticals whereas others are new biotechnology products.
  • The report contains profiles of 141 companies that have neuroprotective products or products along with 126 collaborations.
  • By that time neuroprotection will be an established part of the neurological practice and measures will be available to achieve this effect.

MyMD Pharmaceuticals Announces Issuance of U.S. Patent Covering Lead Drug Candidate MYMD-1 in a Method of Extending Lifespan

Retrieved on: 
Tuesday, November 23, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Sarcopenia, Patent, Ageing, Degenerative disease, Disorder, Inflammation, Diabetes, Forward-looking statement, USPTO, Frailty, Asthma, MS, Multiple sclerosis, Rheumatoid arthritis, Traffic barrier, Central nervous system, Warfarin necrosis, Longevity, COVID-19, Chronic pain, Nasdaq, Cannabidiol, FDA, Thyroiditis, Compte rendu, Intention, Immune system, Fibrosis, Epilepsy, Method, CNS, Disease, TNF, IP, Pharmaceutical industry

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. Patent and Trademark Office (USPTO) today issued U.S. Patent 11,179,382 B2, titled Methods of Reversing Normal Aging Process and Extending Lifespan.

Key Points: 
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. Patent and Trademark Office (USPTO) today issued U.S. Patent 11,179,382 B2, titled Methods of Reversing Normal Aging Process and Extending Lifespan.
  • The allowed claims protect the use of MYMD-1 in a method designed to extend the lifespan of an individual.
  • Our primary focus for MYMD-1 is to slow the aging process, prevent sarcopenia and frailty, and extend healthy lifespan, Dr. Chapman added.
  • Originally developed for autoimmune diseases, MYMD-1s primary purpose is to slow the aging process, prevent sarcopenia and frailty, and extend healthy lifespan.

Global Brain Implants Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 22, 2021
Mental Health, Medical Supplies, Medical Devices, Health, General Health, Biotechnology, Infinity, PD, Abbott, NHS, Hospital, Lists of diseases, CAGR, Awareness, Prevalence, USD, Parkinson, COVID-19, Chronic pain, Physician, Investment, Tremor, Depression, Parkinson's Foundation, North American Neuromodulation Society, Parkinson's disease, Epilepsy, Migraine, Growth, Medical device, Pharmaceutical industry

The "Global Brain Implants Market Size, Share & Trends Analysis Report 2021-2028" has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Brain Implants Market Size, Share & Trends Analysis Report 2021-2028" has been added to ResearchAndMarkets.com's offering.
  • The global brain implants market size is anticipated to reach USD 9.2 billion by 2028.
  • The market is expected to expand at a CAGR of 9.1% from 2021 to 2028.
  • The rise in neurological disorders such as epilepsy, Parkinson's disease, depression, and tremors as well as growing investments in R&D to develop cost-effective brain implants is attributing to the growth of the market.

Amazon Live Influencers, Randal Constant with Special-Needs Son Calvin, Sail Past 75,000 Followers on LinkedIn - While Earning Over 3 Million Views on Popular Food and Product Trends Daily Livestream Show

Retrieved on: 
Monday, November 22, 2021
People, Cerebral palsy, News, Hunger, Income, Partnership, Pinterest, Constant, WDSU, Twitter, Central Time, Human, Blog, Social media, Instagram, Food industry, Food, LinkedIn, Epilepsy, Amazon, Life, YouTube, Online shopping

METAIRIE, La., Nov. 22, 2021 /PRNewswire/ -- Randal Constant , known across the web as the LinkedIn Food Guy, recently announced that his popular Amazon Live show had surpassed three million views.

Key Points: 
  • METAIRIE, La., Nov. 22, 2021 /PRNewswire/ -- Randal Constant , known across the web as the LinkedIn Food Guy, recently announced that his popular Amazon Live show had surpassed three million views.
  • Constant originally gained fame as a popular LinkedIn contributor, amassing over 75,000 followers who followed the course of his long career as a restaurant and food distribution expert.
  • Recently featured in a local news story by WDSU in New Orleans , Calvin is a frequent contributor to Randal's live streams.
  • It started on LinkedIn, where I began to build a large fanbase, and has since moved to Amazon Live."